Effects of Aminoglutethimide and Rogletimide on Breast Cancer
Author Information
Author(s): F.A. MacNeill, A.L. Jones, S. Jacobs, P.E. Lonning, T.J. Powles, M. Dowsett
Primary Institution: Royal Marsden Hospital
Hypothesis
How do Aminoglutethimide and Rogletimide affect aromatase activity in postmenopausal women with advanced breast cancer?
Conclusion
Aminoglutethimide is more effective than Rogletimide in inhibiting aromatase and suppressing estrogen levels in postmenopausal women with advanced breast cancer.
Supporting Evidence
- Aminoglutethimide achieved a mean aromatase inhibition of 90.6%.
- Rogletimide showed dose-dependent aromatase inhibition, peaking at 73.8% at the highest dose.
- Statistical significance was achieved for the differences in aromatase inhibition between the two drugs.
Takeaway
This study looked at two drugs to see how well they stop the body from making a hormone that can help breast cancer grow. One drug worked much better than the other.
Methodology
The study involved 13 postmenopausal women receiving either Aminoglutethimide or Rogletimide, with measurements of aromatase activity and estrogen levels taken before and after treatment.
Potential Biases
Potential biases may arise from the non-randomized nature of the study and the small number of participants.
Limitations
The small sample size limits the ability to generalize the findings.
Participant Demographics
All participants were postmenopausal women with advanced breast cancer.
Statistical Information
P-Value
p<0.01
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website